PL2511264T3 - Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych - Google Patents
Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznychInfo
- Publication number
- PL2511264T3 PL2511264T3 PL12163746T PL12163746T PL2511264T3 PL 2511264 T3 PL2511264 T3 PL 2511264T3 PL 12163746 T PL12163746 T PL 12163746T PL 12163746 T PL12163746 T PL 12163746T PL 2511264 T3 PL2511264 T3 PL 2511264T3
- Authority
- PL
- Poland
- Prior art keywords
- apoptosis
- immune
- cancer
- treatment
- autoimmune diseases
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14562709P | 2009-01-19 | 2009-01-19 | |
| EP12163746.6A EP2511264B1 (en) | 2009-01-19 | 2010-01-15 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP10701083A EP2387560A2 (en) | 2009-01-19 | 2010-01-15 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2511264T3 true PL2511264T3 (pl) | 2015-08-31 |
Family
ID=42026765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12163746T PL2511264T3 (pl) | 2009-01-19 | 2010-01-15 | Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8426422B2 (pl) |
| EP (2) | EP2387560A2 (pl) |
| JP (1) | JP5613176B2 (pl) |
| KR (2) | KR20160066014A (pl) |
| CN (2) | CN106045893A (pl) |
| AU (1) | AU2010204554B2 (pl) |
| BR (1) | BRPI1006116A2 (pl) |
| CA (2) | CA2747835A1 (pl) |
| DK (1) | DK2511264T3 (pl) |
| ES (1) | ES2536090T3 (pl) |
| HR (1) | HRP20150442T1 (pl) |
| HU (1) | HUE025527T2 (pl) |
| IL (2) | IL213623A (pl) |
| MX (1) | MX2011007681A (pl) |
| NZ (3) | NZ616828A (pl) |
| PL (1) | PL2511264T3 (pl) |
| PT (1) | PT2511264E (pl) |
| RU (1) | RU2539587C2 (pl) |
| SG (2) | SG193849A1 (pl) |
| SI (1) | SI2511264T1 (pl) |
| TW (2) | TWI494303B (pl) |
| WO (1) | WO2010083441A2 (pl) |
| ZA (1) | ZA201104672B (pl) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| HUE043326T2 (hu) * | 2008-11-07 | 2019-08-28 | Amgen Res Munich Gmbh | Akut limfoblasztos leukémia kezelése |
| JP5798036B2 (ja) * | 2008-11-07 | 2015-10-21 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 小児急性リンパ芽球性白血病の新規治療 |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| RU2538965C2 (ru) * | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
| NZ616828A (en) | 2009-01-19 | 2015-03-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2546294T7 (es) * | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AU2011229862B2 (en) * | 2010-03-25 | 2014-07-24 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| RU2593231C2 (ru) | 2010-11-23 | 2016-08-10 | ЭббВи Айэленд Анлимитед Компани | Способы лечения с использованием селективных ингибиторов bcl-2 |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| CA2859385A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| KR101229430B1 (ko) * | 2012-07-02 | 2013-02-05 | 대한민국 | 〔ｅ〕ｎ〔５〔２〔２〔２，４다이히드록시벤질리덴〕히드라지닐〕２옥소에틸〕１，３，４티아디아졸２일〕４메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환의 예방 및 치료용 약학적 조성물 |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| RS57569B1 (sr) * | 2013-03-13 | 2018-10-31 | Abbvie Inc | Postupci za pripremanje agensa koji uzrokuje apoptozu |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| EP3102195B1 (en) | 2014-02-03 | 2021-10-06 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| JP6626085B2 (ja) * | 2014-07-15 | 2019-12-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法 |
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| CN107001251A (zh) * | 2014-11-27 | 2017-08-01 | 埃克杜鲁姆房地产有限公司 | 双(磺酰胺)衍生物及其作为mpges抑制剂的用途 |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| AR105592A1 (es) | 2015-08-03 | 2017-10-18 | Quadriga Biosciences Inc | b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS |
| CN107033043B (zh) * | 2016-02-04 | 2019-04-30 | 中国人民解放军第二军医大学 | N-取代苯磺酰基-取代苯甲酰胺类化合物及其制备药物的用途 |
| ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
| GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN106565706B (zh) * | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
| EA202192783A1 (ru) | 2016-12-09 | 2022-02-24 | Вертекс Фармасьютикалз Инкорпорейтед | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора |
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| SI3612531T1 (sl) * | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| TWI651087B (zh) * | 2017-04-21 | 2019-02-21 | Chang Gung University | 類泛素化抑制劑於預防或治療骨質疏鬆症的用途 |
| MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| IL272032B2 (en) | 2017-07-17 | 2026-04-01 | Vertex Pharma | Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and |
| MA49752A (fr) | 2017-08-02 | 2021-04-21 | Vertex Pharma | Procédés de préparation de composés de pyrrolidine |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN112437772B (zh) | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| CN109776414B (zh) * | 2019-01-02 | 2022-04-22 | 山东大学 | 一种Bcl-2蛋白抑制剂及其制备方法和应用 |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| CN115244051B (zh) * | 2020-03-12 | 2024-10-18 | 南京明德新药研发有限公司 | 苯并五元环类化合物 |
| CN116969937B (zh) | 2020-04-15 | 2026-03-24 | 百济神州(苏州)生物科技有限公司 | Bcl-2抑制剂 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| WO2001097855A2 (en) * | 2000-06-20 | 2001-12-27 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| UY26942A1 (es) * | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| SK14642003A3 (sk) * | 2001-06-06 | 2004-12-01 | Eli Lilly And Company | Benzoylsulfónamidy a sulfonylbenzamidíny ako protinádorové činidlá |
| US20030059489A1 (en) | 2001-09-24 | 2003-03-27 | Canolio Inc. | Genital lubricating compositions and uses thereof |
| US7332486B2 (en) | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| US6995787B2 (en) | 2002-08-21 | 2006-02-07 | Adams Steven L | Sports projectile and camera apparatus |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| PL1668002T3 (pl) | 2003-10-03 | 2010-02-26 | Portola Pharm Inc | 2,4-diokso-3-chinazolinyloarylowe pochodne sulfonylomocznika |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| ES2294494T3 (es) | 2004-04-19 | 2008-04-01 | Symed Labs Limited | Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados. |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| ES2493466T3 (es) * | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| EP1888543B1 (en) * | 2005-05-24 | 2012-08-01 | Abbott Laboratories | Apoptosis promoters |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| MX2009002422A (es) * | 2006-09-05 | 2009-03-20 | Abbott Lab | Inhibidores bcl para tratar exceso de plaquetas. |
| SG174772A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
| WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| WO2009055006A1 (en) | 2007-10-26 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| CN101220008B (zh) * | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| NZ614305A (en) * | 2008-12-05 | 2015-03-27 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
| NZ616828A (en) | 2009-01-19 | 2015-03-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2546294T7 (es) | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| AU2011229862B2 (en) | 2010-03-25 | 2014-07-24 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2010
- 2010-01-15 NZ NZ61682810A patent/NZ616828A/en not_active IP Right Cessation
- 2010-01-15 KR KR1020167014664A patent/KR20160066014A/ko not_active Abandoned
- 2010-01-15 NZ NZ703941A patent/NZ703941A/en not_active IP Right Cessation
- 2010-01-15 PL PL12163746T patent/PL2511264T3/pl unknown
- 2010-01-15 EP EP10701083A patent/EP2387560A2/en not_active Withdrawn
- 2010-01-15 HU HUE12163746A patent/HUE025527T2/en unknown
- 2010-01-15 CA CA2747835A patent/CA2747835A1/en not_active Abandoned
- 2010-01-15 JP JP2011546401A patent/JP5613176B2/ja not_active Expired - Fee Related
- 2010-01-15 CA CA2936120A patent/CA2936120A1/en not_active Abandoned
- 2010-01-15 MX MX2011007681A patent/MX2011007681A/es active IP Right Grant
- 2010-01-15 NZ NZ593593A patent/NZ593593A/xx not_active IP Right Cessation
- 2010-01-15 CN CN201610390761.1A patent/CN106045893A/zh active Pending
- 2010-01-15 WO PCT/US2010/021243 patent/WO2010083441A2/en not_active Ceased
- 2010-01-15 ES ES12163746.6T patent/ES2536090T3/es active Active
- 2010-01-15 DK DK12163746.6T patent/DK2511264T3/da active
- 2010-01-15 EP EP12163746.6A patent/EP2511264B1/en active Active
- 2010-01-15 RU RU2011134634/04A patent/RU2539587C2/ru not_active IP Right Cessation
- 2010-01-15 PT PT121637466T patent/PT2511264E/pt unknown
- 2010-01-15 SI SI201030944T patent/SI2511264T1/sl unknown
- 2010-01-15 SG SG2013066071A patent/SG193849A1/en unknown
- 2010-01-15 CN CN2010800047718A patent/CN102282129A/zh active Pending
- 2010-01-15 BR BRPI1006116A patent/BRPI1006116A2/pt not_active IP Right Cessation
- 2010-01-15 SG SG2011046836A patent/SG172391A1/en unknown
- 2010-01-15 KR KR1020117018581A patent/KR101661126B1/ko not_active Expired - Fee Related
- 2010-01-15 AU AU2010204554A patent/AU2010204554B2/en not_active Ceased
- 2010-01-18 TW TW104101224A patent/TWI494303B/zh not_active IP Right Cessation
- 2010-01-18 US US12/689,106 patent/US8426422B2/en not_active Expired - Fee Related
- 2010-01-18 TW TW99101256A patent/TWI472527B/zh not_active IP Right Cessation
-
2011
- 2011-06-16 IL IL213623A patent/IL213623A/en not_active IP Right Cessation
- 2011-06-23 ZA ZA2011/04672A patent/ZA201104672B/en unknown
-
2015
- 2015-04-23 HR HRP20150442TT patent/HRP20150442T1/hr unknown
- 2015-05-04 IL IL238607A patent/IL238607A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI561523B (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| IL238607A0 (en) | Apoptosis-inducing factors for the treatment of cancer and immune and autoimmune diseases | |
| IL219991A0 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| ZA201104671B (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| IL247183B (en) | Secretory-apoptosis factors for the treatment of cancer and immune and autoimmune diseases | |
| IL233832B (en) | Agents that induce programmed cell death for the treatment of cancer, immune diseases and immunodeficiency diseases | |
| ZA201208832B (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| IL231702A0 (en) | Factors that induce programmed cell death for the treatment of cancer and immune and auto-immune diseases | |
| IL231926A0 (en) | Apoptosis-inducing factors for the treatment of cancer and immune and autoimmune diseases | |
| HK1163057A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |